Sugi Predict

Sugi Predict / Compounds / SCHEMBL1665299

SCHEMBL1665299

SCHEMBL1665299

COc1ccc(-c2cc3ccc(OC)cc3s2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ TP53 P04637 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ TSHR P16473 1/20 0.56
▸ NFKB1 P19838 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ NFKB2 Q00653 1/20 0.56
▸ RELA Q04206 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ APP P05067 5/20 0.55
▸ HDAC6 Q9UBN7 1/20 0.52
▸ ESR1 P03372 3/20 0.51
▸ ESR2 Q92731 3/20 0.51
▸ CA2 P00918 1/20 0.51
▸ IKBKB O14920 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31310542 1.00 NPC1 (0.56) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL6838658 0.90 APP (0.57) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL26625361 0.90 NPC1 (0.48) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL205800 0.90 HDAC6 (0.48) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL3053766 0.90 APP (0.58) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL6171301 0.90 ESR2 (0.68) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL6832572 0.90 ESR1 (0.58) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL7636669 0.89 HDAC6 (0.50) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL7641283 0.89 NPC1 (0.47) NPC1ALDH1A1TP53MAPTHPGD
SCHEMBL5681634 0.88 ESR1 (0.58) NPC1ALDH1A1TP53MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116332901-B Raloxifene derivative with room temperature phosphorescence characteristic and application thereof 华东理工大学 2025-02-25 — — CN claimed
CN-117085143-A PROTACs nano blocking agent for estrogen receptor and preparation method and application thereof 郑州大学 2023-11-21 — — CN claimed
CN-116332901-A Raloxifene derivative with room temperature phosphorescence characteristic and application thereof 华东理工大学 2023-06-27 — — CN claimed
WO-2011132194-A1 PROCESS FOR THE PREPARATION OF RALOXIFENE HYDROCHLORIDE HETERO RESEARCH FOUNDATION (IN) 2011-10-27 — — WO claimed
WO-2005003116-A9 PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE ERREGIERRE SPA (IT) 2008-09-25 — — WO claimed
EP-1641773-B1 PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE ERREGIERRE SPA (IT) 2008-07-23 — — EP claimed
US-20070100147-A1 Process for preparing raloxifene hydrochloride ERREGIERRE S.P.A (IT) 2007-05-03 — — US claimed
EP-1641773-A1 PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE ERREGIERRE S.p.A. (IT) 2006-04-05 — — EP claimed
WO-2005003116-A1 PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE ERREGIERRE S.P.A. (IT) 2005-01-13 — — WO claimed
US-6395769-B1 ACTIVATION ESTROGEN; THERAPY FOR OSTEOPOROSIS, ANTILIPEMIC AGENTS ELI LILLY AND COMPANY 2002-05-28 — — US claimed
US-6096781-A 2-PHENYL-1-BENZOTHIOPHENE DERIVATIVES ARE USEFUL FOR TREATMENT OF OSTEOPOROSIS AND HYPERLIPEMIA ELI LILLY AND COMPANY (US) 2000-08-01 — — US claimed
EP-0920862-A1 2-Arylbenzo b thiophenes useful for the treatment of estrogen deprivation syndrome ELI LILLY AND COMPANY (US) 1999-06-09 — — EP claimed
WO-1999025707-A1 2-ARYLBENZO[b]THIOPHENES USEFUL FOR THE TREATMENT OF ESTROGEN DEPRIVATION SYNDROME ELI LILLY AND COMPANY (US) 1999-05-27 — — WO claimed
US-5827876-A MODIFYING BALANCE BETWEEN BONE RESORPTION AND PRODUCTION AMERICAN HOME PRODUCTS CORPORATION (US) 1998-10-27 — — US claimed
US-12398121-B2 Anti-cancer nuclear hormone receptor-targeting compounds NUVATION BIO INC. (US) 2025-08-26 — — US disclosed
US-12383624-B2 Cargo delivery system and composition comprising the same SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-08-12 — — US disclosed
CN-116332901-B Raloxifene derivative with room temperature phosphorescence characteristic and application thereof 华东理工大学 2025-02-25 — — CN disclosed
EP-0062503-A1 Benzothiophene compounds and process for preparing them ELI LILLY AND COMPANY (US) 1982-10-13 — — EP disclosed
EP-0062504-A1 Process for preparing 3-(4-aminoethoxybenzoyl)benzo(b)thiophenes ELI LILLY AND COMPANY (US) 1982-10-13 — — EP disclosed
US-4133814-A ANTITUMOR AGENTS ELI LILLY AND COMPANY (US) 1979-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100147-A1 Process for preparing raloxifene hydrochloride KAT2A, ADH1A, KAT2B NPC1 4666/4885ALDH1A1 152/4885TP53 3036/4885
US-12398121-B2 Anti-cancer nuclear hormone receptor-targeting compounds NCOA1, NCOR1, NCOA3 NPC1 518/4885ALDH1A1 3398/4885TP53 55/4885
US-12383624-B2 Cargo delivery system and composition comprising the same ATG7, SQSTM1, BECN1 NPC1 86/4885ALDH1A1 4664/4885TP53 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.